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The clinical relevance of mismatches at the MHC class Ierelated chain A (MICA) in hematopoietic stem cell
transplantation (HSCT) remains unclear. We investigated the association of MICA donor/recipient mismatch
and whether there is an interaction between these and HLA-DPB1 mismatch on clinical outcomes after
unrelated donor HSCT. Our study included 227 patients who underwent unrelated donor allogeneic HSCT at
our institution between 2000 and 2010. Among these, 177 (78%) received HSCT from a 10/10 HLA-matched
donor. MICA genotyping was performed using commercially available kits. In univariable analysis, the risk
of grade II to IV acute graft-versus-host disease (GVHD) was greater for patients with MICA mismatch (hazard
ratio [HR], 1.73; P ¼ .02) than for those with HLA-DPB1 mismatch (HR, 1.62; P ¼ .07). When MICA and HLA-
DPB1 were assessed simultaneously, patients mismatched at both loci had the greatest risk (HR, 2.51; P < .01)
and those mismatched at only 1 locus had somewhat greater risk (HR, 1.53; P ¼ .12) than patients matched at
both loci; this remained signiﬁcant in multivariable analysis. The 100-day incidence was 66%, 45%, and 31%,
respectively (P ¼ .03). Results were similar for grade III and IV acute GVHD, with 100-day incidence 34%, 16%,
and 8% (P ¼ .01). These results are clinically pertinent to donor selection strategies and indicate that patients
with mismatch at both MICA and HLA-DPB1 are at increased risk for acute GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The impact of donor recipient matching at human
leukocyte antigen (HLA) on clinical outcomes of unrelated
hematopoietic stem cell transplantation (HSCT) has been
established by large international registry studies [1,2].
However, even in patients who receive grafts with high-dgments on page 1839.
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ty for Blood and Marrow Transplantation.resolution matching at HLA-A, -B, -C, -DRB1, and -DQB1
loci, acute graft-versus-host disease (GVHD) remains a major
cause of post-transplantation morbidity and mortality [3].
The clinical relevance of mismatches at other genetic loci
remains unclear. An example of such loci is the MHC class I
chainerelated gene A (MICA) gene that is located 46 Kb
(Figure 1) centromeric to the HLA-B locus on the short arm of
human chromosome 6 and encodes for a 62-kd cell surface
glycoprotein [4]. It is expressed on endothelial cells, dendritic
cells, ﬁbroblasts, epithelial cells, and many tumors, and it
serves as target for both cellular and humoral immune re-
sponses in transformed cells [5,6]. MICA protein at normal
states has a low level of expression in epithelial tissues but is
Figure 1. Chromosomal location of MICA genes shown on a map of the MHC on chromosome 6p21.3 (not to scale). Chromosome 6 drawing modiﬁed from the
National Library of Medicine, the National Center for Biotechnology Information public website [22].
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including heat shock proteins [7]. It has been recently re-
ported that multiple mismatches at the low-expression HLA
loci DPB1, DQB1, and DRB3/4/5 are associated with adverse
outcomes in HSCT [8]. As a low-expression antigen, whether
MICA mismatch has an additive impact to mismatch at other
low-expression loci also remains unclear. In this study, we
investigated the impact of MICA donor/recipient mismatches
and whether there is an additive effect of mismatch at MICA
and HLA-DPB1 loci on clinical outcomes after unrelated
donor HSCT.METHODS
Study Population
The study included 227 of 269 patients who had allogeneic HSCT using
an unrelated donor in our institution from 2000 to 2010 and had samples
available for MICA testing. Patients who received stem cells from related
donors or cord blood units were excluded. This study was approved by
Cleveland Clinic’s institutional review board. HLA matching was considered
as 8/8 (n ¼ 181, 80%) versus <8/8 (n ¼ 46, 20%) matches at HLA-A,-B,-C,
and -DRB1 loci and as 10/10 (n ¼ 177, 78%) versus <10/10 (n ¼ 50, 22%)
matches with the inclusion of HLA-DQB1 locus. Patients included 129
males (57%) and 214 Caucasians (94%). The median age at transplantation
was 46 (range, 7 to 70) years. Two patients had aplastic anemia and 1
patient had paroxysmal nocturnal hematuria. The remaining 224 patients
received HSCT for hematological malignancies (83 acute myeloid leukemia,
37 acute lymphoblastic leukemia, 37 myelodysplastic syndromes, 26 non-
Hodgkin lymphoma, 13 chronic myeloid leukemia, 8 chronic lymphocytic
leukemia, and 20 other hematologic malignancies). Hematopoietic pro-
genitor cell sources included bone marrow in 138 (61%) and peripheral
blood progenitor cells in 89 (39%) patients. The median CD34þ dose was
3.54  106/kg (range, .38 to 11.55) and median total nucleated cell dose was
2.73  108/kg (range, .02 to 28.55). Myeloablative and reduced-intensity
conditioning regimens were used in 167 (74%) and 60 (26%) patients,
respectively. GVHD prophylaxis consisted of a calcineurin inhibitor and
mycophenolate or methotrexate.MICA Genotyping
MICA genotyping was performed on stored genomic DNA samples using
commercially available Luminex based rSSOP Kits (Thermo Fisher Scientiﬁc,
One Lambda, CA).Outcomes Analyzed
The primary endpoint was acute GVHD. Timing of acute GVHD was
calculated from the date of transplantation until the date of acute GVHD or
last follow-up. Death without acute GVHDwas analyzed as a competing risk.
Three acute GVHD outcomes were assessed: any, grade II to IV, and grade III
to IV.Statistical Analysis
Descriptive statistics included mean and standard deviation or median
and range for continuous variables, and frequency counts and percentages
for categorical variables. The chi-squared test or Fisher exact test was used to
compare HLA variables between MICA-matched and -mismatched patients
and to compare all study variables among groups based on MICA and HLA-
DPB1 mismatch. Cumulative incidence estimates of acute GVHD were
calculated and compared among MICA- and DPB1-mismatch groups using
the Gray test [9].
To assess possible synergistic effect of mismatches at both MICA and
HLA-DPB1, 4 groups were considered: no mismatch at MICA or DPB1 (G0),
mismatch at MICA only (G1-a), mismatch at HLA-DPB1 only (G1-b), or
mismatch at MICA and DPB1 (G2).
Univariable and multivariable risk factors for acute GVHD were identi-
ﬁed using Fine and Gray competing risk regression [10]. The following
variables were analyzed as potential risk factors in univariable analysis:
gender, age, hematopoietic cell transplantationespeciﬁc comorbidity index,
number of prior chemotherapy regimens, prior radiation, diagnosis type
(myeloid, lymphoid, other), intensity of conditioning regimen (myeloa-
blative, reduced intensity), source of hematopoietic cells, T cell depletion,
donor-recipient gender, CD34þ dose, total nucleated cell dose, HLA-match
(10/10 or <10/10), DRB3/4/5 mismatch, DPB1 mismatch, MICA mismatch,
and the variable for the combined MICA and DPB1 mismatch.
Because the primary objective was to assess the combined effect of
MICA and HLA-DPB1 mismatch, this combined variable was included in all
multivariable models. Mismatches at HLA-DPB1 were reported in associa-
tion with diverging clinical effects with deleterious effect in 10/10 HLA-
matched transplantations but advantageous effect in 9/10 matched trans-
plantations [11]. Therefore, all multivariable models also included a variable
to account for <10/10 HLA match. Other accepted risk factors for acute
GVHD include age, intensity of conditioning, source of hematopoietic cells, T
cell depletion, donor-recipient gender, and GVHD prophylaxis regimen. T
cell depletion and donor-recipient genderwere not signiﬁcant in univariable
analysis and were excluded from multivariable analysis for parsimony.
GVHD prophylaxis regimen was excluded because it is almost perfectly
correlated with intensity of conditioning. Therefore, multivariable models
for acute GVHD assessed the effect of MICA and HLA-DPB1 mismatch after
adjusting for HLA mismatch, age, intensity of conditioning, and hemato-
poietic cell source.
Competing risk regression was done in R with the cmprsk package
(Linux version 3.0.0, http://www.r-project.org/); all other analyses were
done with SAS version 9.2 (SAS Institute Inc., Cary, NC). All statistical tests
were 2-sided. A P value < .05 was considered statistically signiﬁcant.
RESULTS
Forty-two patients who did not have samples available for
MICA testing were compared to 227 study patients. These 42
patients were from earlier transplantations in this series, but
they were otherwise similar to study patients with respect to
baseline characteristics (results not shown). Among 227
patients, 31 (14%) were mismatched for MICA (28 patients
Table 1
Distribution of Mismatches at Different HLA Loci Among Patients with and
without MICA Mismatches
Variable No MICA Mismatch
(n ¼ 196)
One or Two MICA
Mismatch (n ¼ 31)
P Value
HLA-A mismatch
0 183 (93.4) 26 (83.9) .08
1 13 (6.6) 5 (16.1)
HLA-B mismatch
0 195 (99.5) 30 (96.8) .26
1 1 (.5) 1 (3.2)
HLA-C mismatch
0 178 (90.8) 23 (74.2) .01
1-2 18 (9.2) 8 (25.8)
HLA-DRB1 mismatch
0 194 (99) 30 (96.8) .36
1 2 (1) 1 (3.2)
HLA-DQB1 mismatch
0 187 (95.4) 27 (87.1) .08
1 9 (4.6) 4 (12.9)
HLA match
<8/8 33 (16.8) 13 (41.9) <.01
8/8 163 (83.2) 18 (58.1)
<10/10 37 (18.9) 13 (41.9) <.01
10/10 159 (81.1) 18 (58.1)
DRB3/4/5 mismatch
0 181 (92.3) 29 (93.5) 1.0
1 15 (7.7) 2 (6.5)
DPB1 mismatch*
0 39 (19.9) 2 (6.5) .15
1 102 (52) 17 (54.8)
2 55 (28.1) 12 (38.7)
Data presented are n (%).
* DPB1 mismatch (P ¼ .07 comparing 0 versus 1 and 2 DPB1 mismatches
between MICA groups).
Table 2
Distribution of Mismatches at Different HLA Loci among Patients based on
the Three-Group Variable
Variable G0 (n ¼ 39) G1 (n ¼ 159) G2 (n ¼ 29) P Value
HLA-A mismatch
0 38 (97.4) 147 (92.5) 24 (82.8) .10
1 1 (2.6) 12 (7.5) 5 (17.2)
HLA-B mismatch
0 39 (100.0) 158 (99.4) 28 (96.6) .30
1 0 1 (.6) 11 (3.4)
HLA-C mismatch
0 35 (89.7) 144 (90.6) 22 (75.9) .09
1-2 4 (10.3) 15 (9.4) 77 (24.1)
HLA-DRB1 mismatch
0 39 (100.0) 157 (98.7) 28 (96.6) .40
1 0 2 (1.3) 11 (3.4)
HLA-DQB1 mismatch
0 39 (100.0) 150 (94.3) 25 (86.2) .04
1 0 9 (5.7) 44 (13.8)
HLA match
<8/8 5 (12.8) 29 (18.2) 12 (41.4) <.01
8/8 34 (87.2) 130 (81.8) 17 (58.6)
<10/10 5 (12.8) 33 (20.8) 12 (41.4) .02
10/10 34 (87.2) 126 (79.2) 17 (58.6)
DRB3/4/5 mismatch
0 36 (92.3) 147 (92.5) 27 (93.1) 1.0
1 3 (7.7) 12 (7.5) 22 (6.9)
G0 indicates no mismatch at DPB1 or MICA; G1, mismatch at DPB1 only or
MICA only; G2, mismatch at DPB1 and MICA.
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distribution of mismatches at different HLA loci among pa-
tients with and without MICA mismatches is shown in
Table 1. Compared with pairs with 0 MICAmismatches, 1 and
2MICAmismatches were signiﬁcantly more likely to be<10/
10 match (42% versus 19%, P < . 01) and to have more HLA-C
mismatches (26% versus 9%, P ¼ .01) and somewhat more
mismatches in HLA-A (16% versus 7%, P ¼ .08), HLA-DQB1
(13% versus 5%, P ¼ .08), and HLA-DPB1 (94% versus 80%,
P ¼ .07). There were no signiﬁcant differences in mismatches
at other loci among the 2 groups.
Of all patients, 186 (82%) were mismatched for HLA-DPB1
(119 had 1 mismatch and 67 had 2 mismatches). Based on
mismatches at both MICA and HLA-DPB1 loci, 39 patients
had no mismatch at MICA or DPB1 (G0), 2 had mismatch at
MICA only (G1-a), 157 had mismatch at DPB1 only (G1-b),
and 29 had mismatch at both MICA and DPB1 (G2). Because
of the small number of patients with mismatch at MICA only
(G1-a), this group was combined with G1-b into a single
category with mismatch at DPB1 only or MICA only (G1). The
distribution of mismatches at different HLA loci among pa-
tients based on the 3-group variable for MICA and DPB1
mismatch is shown in Table 2. Patients with mismatches at
both MICA and HLA-DPB1 tended to have higher HLA-DQB1
mismatches (14% versus 6% in those with mismatch at either
MICA or HLA-DPB1 and 0% in those with no mismatches at
both loci, P ¼ .04) and higher rate of being <10/10 matched
(41% versus 21% and 13%, respectively; P ¼ .02). There were
no signiﬁcant differences in mismatches at other loci among
the 3 groups. In this cohort, only 13 patients were mis-
matched at DQB1 and 17 at HLA-DRB3, -DRB4, or -DRB5 loci,
which precluded meaningful assessment of a possible addi-
tive effect of mismatches at MICA to those at DQB1 or DRB3/4/5. There were no signiﬁcant differences among the groups
regarding disease diagnoses, graft source, ages, conditioning
regimen, and GVHD prophylaxis (Supplemental Table 1).
Results were similar among the 2 subset analyses, 10/10
and 8/8, and therefore, only results for all patients and the
subset of patients with 10/10 HLA-matched transplantations
are presented. These analyses focused on MICA, DPB1, and
the combined MICA/DPB1 variable.
The associations between acute GVHD and MICA mis-
matches, HLA-DPB1 mismatches, and the 3 groups based on
combined MICA/HLA-DPB1 mismatch are shown in Table 3.
Overall, 68% of patients developed acute GVHD (21% grade I,
29% II, 9% III, and 10% IV), and 42% developed chronic GVHD
(17% limited and 25% extensive).
Compared with 0 MICA mismatches, presence of 1 and 2
mismatches was associated with higher risk of grade II to IV
acute GVHD (hazard ratio [HR], 1.73; 95% conﬁdence interval
[CI], 1.07 to 2.79; P¼ .02) and grade III and IV acute GVHD (HR,
2.86; 95% CI,1.48 to 5.51; P< .01). The associationwith grade III
and IV acute GVHD remained signiﬁcant in the subset of pa-
tients with 10/10 HLAmatching (HR, 2.86; 95% CI, 1.27 to 6.42;
P ¼ .01). Compared with 0 HLA-DPB1, 1 and 2 mismatches at
HLA-DPB1 were associated with higher risk of grade I to IV
acuteGVHDinall patients (HR,1.57;95%CI,1.03 to2.40;P¼ .03)
and in 10/10 patients (HR, 1.79; 95% CI, 1.11 to 2.89; P ¼ .02).
Compared with patients with no mismatches at either
MICA or HLA-DPB1 (G0), patients with mismatches at both
loci (G2) had signiﬁcantly greater risk of grade II to IV acute
GVHD (HR, 2.51; 95% CI, 1.30 to 4.87; P < .01) and grade III
and IV acute GVHD (HR, 4.38; 95% CI, 1.42 to 13.5, P ¼ .01);
these ﬁndings remained signiﬁcant in multivariable analysis
(Table 4). In G0, G1, and G2 patients, 100-day cumulative
incidence of grade II to IV acute GVHDwas 31%, 45%, and 66%,
respectively (P ¼ .03). The 100-day incidence of grade III and
IV acute GVHD was 8%, 16%, and 34%, respectively (Figure 2)
(P ¼ .01).
In the subset analysis of patients receiving 10/10 HLA-
matched transplants, we observed an increase in the risk of
Table 3
Association between Acute GVHD and MICA Mismatches, HLA-DPB1 Mismatches, and the Three Groups, Based on Combined MICA/HLA-DPB1 Mismatch
Outcome All Patients (n ¼ 227) P Value 10/10 HLA-Matched Recipients (n ¼ 177) P Value
HR (95% CI) HR (95% CI)
Any acute GVHD
1-2 MICA mismatch versus no MICA mismatch 1.18 (.77-1.82) .44 1.05 (.62-1.76) .86
1-2 DPB1 mismatch versus no DPBI mismatch 1.57 (1.03-2.40) .03 1.79 (1.11-2.89) .02
G1 versus G0 1.52 (.99-2.35) .06 1.69 (1.04-2.74) .03
G2 versus G0 1.74 (.99-3.05) .06 1.76 (.93-3.34) .08
Grade 2-4 acute GVHD
1-2 MICA mismatch versus no MICA mismatch 1.73 (1.07-2.79) .02 1.25 (.68-2.30) .47
1-2 DPB1 mismatch versus no DPBI mismatch 1.62 (.97-2.71) .07 1.88 (1.03-3.46) .04
G1 versus G0 1.53 (.89-2.63) .12 1.76 (.95-3.26) .07
G2 versus G0 2.51 (1.30-4.87) <.01 2.14 (.97-4.72) .06
Grade 3-4 acute GVHD
1-2 MICA mismatch versus no MICA mismatch 2.86 (1.48-5.51) <.01 2.86 (1.27-6.42) .01
1-2 DPB1 mismatch versus no DPBI mismatch 1.74 (.70-4.34) .23 1.76 (.62-4.94) .29
G1 versus G0 1.75 (.62-4.92) .29 1.41 (.49-4.05) .53
G2 versus G0 4.38 (1.42-13.5) .01 4.05 (1.23-13.4) .02
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DPB1 mismatches, although this did not reach statistical
signiﬁcance and likely reﬂected the limitation of a relatively
small sample size (compared with G0, HR, 1.76; 95% CI, .95 to
3.26; P ¼ .07 for G1 and HR, 2.14; 95% CI, .97 to 4.72; P ¼ .06
for G2). Similar results were observed for grade III and IV
acute GVHD (compared with G0, HR, 1.41; 95% CI, .49 to 4.05;
P ¼ .53 for G1 and HR, 4.05; 95% CI, 1.23 to 13.4; P ¼ .02 for
G2). In univariable analysis, there was no evidence of sig-
niﬁcant differences in the incidence of GVHD (any or grades II
to IV) among G1 and G2 patients (HR,1.04; 95% CI, .62 to 1.74;
P¼ .88 and HR,1.22; 95% CI, .66 to 2.25; P¼ .53, respectively).
However, compared with G1 patients, G2 patients had
signiﬁcantly higher risk of grade III and IV acute GVHD (HR,
2.88; 95% CI, 1.26 to 6.59; P ¼ .01).DISCUSSION
In our retrospective analysis, we demonstrate a signiﬁ-
cant association between MICA mismatches and acute grade
III and IV GVHD in unrelated donor HSCT recipients. This
association is consistent with that reported by Parmar et al.,
who reported a higher rate of acute GVHD in MICA-
mismatched patients, regardless of degree of HLA matching
[12]. However, our results are not consistent with those re-
ported by Anderson et al. [13]. In the latter study, the number
of cases analyzed was smaller (n ¼ 48), all cases were
matched for HLA-DPB1, and the rate of MICA mismatch was
lower (2.6%). It is expected that MICA mismatch would be
low in 10/10 HLA-matched pairs because of the strong link-
age disequilibrium between MICA and HLA-B [14]. However,
the remarkably lower incidence of MICA mismatch in
Anderson’s study that contrasts with the 12.7% and 8.5%
MICA-mismatch rates observed in our and Parmar’s study,Table 4
Multivariable Models for Acute GVHD* in the Three Groups, based on Combined M
Variable Any G
HR (95% CI) P Value H
DPB1 and MICA mismatch
G1/G0 1.48 (.96-2.30) .08 1.
G2/G0 1.77 (1.01-3.10) .044 2.
G2/G1 1.19 (.77-1.85) .43 1.
* The multivariable models for acute GVHD assessed the effect of MICA and
conditioning, and hematopoietic cell source.respectively, could be explained, at least in part, by a po-
tential selection bias of 12/12 HLA-matched pairs.
In spite of the growing body of literature that implicates
HLA-DPB1 mismatches with GVHD risk, some in-
consistencies remain among published reports suggesting
that HLA-DPB1 mismatch may not be universally deleterious
[11,15]. In our study, HLA-DPB1 mismatch was associated
with increased risk of any acute GVHD and also associated
with increased risk of grade II to IV acute GVHD in all patients
and 10/10 transplantations. Observing an effect of HLA-DPB1
mismatching only in 10/10 transplantations is consistent
with a previous study reporting a signiﬁcant survival
advantage in HLA-DPB1ematched 10/10 transplantations in
those with early leukemia [11]. The same study also reported
a paradoxical survival advantage of HLA-DPB1 mismatching
in 9/10 transplantations. Overall, observed associations be-
tween HLA- DPB1 mismatch and acute GVHD did not
translate into differences in survival. However, in our study,
we included nonleukemia patients and, because of the
relatively small number of patients, were not able to conduct
subgroup analysis by disease stage.
There was no evidence of association between HLA-DPB1
mismatch and the risk of grade III to IV acute GVHD in this
cohort. However, the multivariable model shows that pa-
tients with mismatches at either MICA or HLA-DPB1 had
somewhat higher risk of grade III and IV acute GVHD
compared with those with no mismatch at MICA or HLA-
DPB1 (HR, 1.75). Interestingly, patients with mismatch at
both MICA and HLA-DPB1 had a signiﬁcantly higher risk of
grade III and IV acute GVHD compared with those with no
mismatch (HR, 4.44) and still signiﬁcantly higher risk
compared with those with mismatches at either of the 2 loci
(HR, 2.54). These ﬁndings demonstrate a synergistic effect of
mismatches at both MICA and HLA-DPB1 loci.ICA/HLA-DPB1 Mismatch
rade II to IV Grade III and IV
R (95% CI) P Value HR (95% CI) P Value
47 (.86-2.51) .16 1.75 (.62-4.91 ) .29
47 (1.28-4.76) .007 4.44 (1.39-14.1) .012
69 (1.03-2.77) .039 2.54 (1.26-5.12) .009
HLA-DPB1 mismatch after adjusting for HLA mismatch, age, intensity of
Figure 2. Synergy between MICA and HLA-DPB1 mismatch for GVHD. Shown
is the cumulative incidence of Grade III and IV acute GVHD for G2 (mismatch
at both loci), G1 (mismatch at either of the 2 loci), and G0 (no mismatch at
either of the 2 loci).
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mismatch in the development of acute GVHD, as a tissue
antigen expressed on endothelial and epithelial cells that can
elicit both humoral and cellular alloresponses [6]. In addi-
tion, it may provide an appropriate biologic context for un-
derstanding the impact of HLA-DPB1 mismatching on GVHD.
A number of hypotheses have been proposed to explain the
apparent differential deleteriousness of such mismatch. The
degree of “permissiveness” or immunogenicity of HLA-DPB1
mismatch has been shown in a large Center for International
Bone Marrow Transplant Research study to be associated
with a differential effect of HLA-DPB1 mismatch [16]. Still, at
least 1 single center report showed no evidence that
nonpermissive DPB1 mismatch was associated with wors-
ened overall survival, relapse risk, or risk of acute GVHD [17].
Matching degree at other loci has also been proposed to
explain the differential effect of HLA-DPB1 mismatch [11]. It
is noteworthy that the probability of HLA-DPB1 mismatch
high-resolution matching in 10/10 HLA-matched pairs is
about 10% to 15% because of weak linkage disequilibrium
between HLA-DPB1 and the other HLA class II loci [18]. In
addition, considering the impact of HLA-DPB1 mismatch on
clinical outcomes in isolation from matching at other loci is
inherently fraught with grouping 2 distinct levels of HLA
mismatching. One level includes those in which HLA-DPB1
mismatches are the result of 2 HLA matched but haplotype
mismatched (matched alleles are inherited on different
chromosomes in the donor and recipient). The other level
includes those inwhich HLA-DPB1mismatches are the result
of haplotype recombination at the hot spot between HLA-
DPB1 mismatch and HLA-DQB1 in otherwise matched HLA
haplotypes (matched alleles are inherited on the same
chromosomes in the donor as the recipient) [19]. MHC
haplotype mismatching was reported in association with a
statistically signiﬁcantly increased risk of severe acute GVHD
[20]. HLA haplotypes are known to harbor single nucleotide
polymorphisms that are associated with GVHD [21]. How-
ever, the methodology proposed for discerning the phase of
haplotypes for matching, thus far, is neither robust enough
nor commonly available for routine clinical testing. In addi-
tion to being tissue antigens themselves, MICA mismatch
might be a surrogate marker of haplotype mismatch using a
commonly available methodology. By virtue of its genomic
location on chromosome 6 between class I and class II MHC,MICA-mismatched donor/recipient pairs would be predicted
to have mismatched haplotypes, whereas the MICA matched
pairs may or may not be haplotype matched. This distinction
could also provide a biologically relevant context for inter-
preting results of studies attempting to correlate DP
mismatch with HSCT clinical outcomes.
Our study is limited by the retrospective design that is
liable to potential selection bias and the relatively small
number of cases. Nevertheless, these results indicate that
MICA mismatches are associated with signiﬁcantly higher
risk of both grade II to IV and grade III and IV acute GVHD in
HSCT recipients from unrelated adult donors and appear to
have a synergistic effect to HLA-DPB1 mismatches. These
observations are clinically relevant particularly as pertains to
prioritization of unrelated donor typing and matching and
warrant further investigation in larger cohorts.ACKNOWLEDGMENTS
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